Skip to content
Clinical Trials – home
LithuaniaBack to Lithuania

Clinical trials in Seskine – page 15

191 clinical trials in Seskine, Lithuania. Every trial is listed in the EU Clinical Trials Register and updated daily.

LithuaniaOur site in LithuaniaKlinikiniai-Tyrimai.lt(opens in a new tab)
Seskine at a glance
191
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

191 trials in Seskine

Open in trial search

Crohn's disease

Not recruiting

Study on the Long-Term Safety and Effectiveness of Upadacitinib for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Asthma

Not recruiting

Study on the Effectiveness and Safety of Tanimilast for Patients with Uncontrolled Asthma on Inhaled Corticosteroid and Long-Acting Beta2-Agonist Therapy

Investigational
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Tanimilast
  • Sponsor:Chiesi Farmaceutici S.p.A.

Alport's syndrome

Not recruiting

Study on the Safety and Effects of Setanaxib for Patients with Alport Syndrome

Investigational
Countries:LithuaniaLithuania
  • Participants:18–64 years
  • Substances:Setanaxib
  • Sponsor:Calliditas Therapeutics Suisse S.A.

Study of Pembrolizumab and Olaparib with Chemoradiation for Patients with Stage III Non-Small Cell Lung Cancer

Registered drug
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study of Pembrolizumab and Olaparib with Chemoradiation for Patients with Newly Diagnosed Limited-Stage Small Cell Lung Cancer

Registered drug
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Partial seizures

Not recruiting

Study of EQU-001 and Placebo for Patients with Uncontrolled Focal Seizures in Epilepsy

Registered drug
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Ivermectin
  • Sponsor:Equilibre Biopharmaceuticals B.V.

Study on Selexipag and Bosentan for Children with Pulmonary Arterial Hypertension

Registered drug
Countries:LithuaniaLithuania
  • Participants:0–17 years
  • Substances:Bosentan
  • Sponsor:Actelion Pharmaceuticals Ltd.

Study on Darolutamide and Androgen Deprivation Therapy for Men with Metastatic Hormone-Sensitive Prostate Cancer

Registered drug
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Bayer AG

Hidradenitis

Not recruiting

Study to Evaluate the Effectiveness of Spesolimab for Patients with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Neoplasm malignant

Not recruiting

Continued Darolutamide Treatment for Cancer Patients from Previous Bayer Studies

InvestigationalNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Bayer Consumer Care AG

Study on Milvexian for Preventing Stroke in Patients with Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Registered drug
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen Cilag International

Endometrial cancer

Not recruiting

Study of Navtemadlin as Maintenance Therapy for Patients with Advanced or Recurrent Endometrial Cancer After Chemotherapy

Registered drug
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Loperamide
  • Sponsor:Kartos Therapeutics Inc.

Other cities in Lithuania

The busiest research cities in the country

All 10 cities in Lithuania
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.